- Home
- PAVM vs KZIA Comparison
PAVM vs KZIA Comparison
Compare PAVM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Australia |
| Employees | 41 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 93.2M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | PAVM | KZIA |
|---|---|---|
| Price | $10.04 | $7.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $510.00 | $17.67 |
| AVG Volume (30 Days) | 10.6K | ★ 107.0K |
| Earning Date | 05-14-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $64.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.66 |
| 52 Week High | $28.44 | $17.40 |
Technical Indicators
Market Signals| Indicator | PAVM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 47.71 |
| Support Level | $8.47 | $6.44 |
| Resistance Level | $10.98 | $8.05 |
| Average True Range (ATR) | 0.57 | 0.68 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 76.78 | 26.04 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.